Rapid development of a transferable R aman model using high‐throughput cell culture for monitoring monoclonal antibody titer
Biotechnology Progress · 2026-05 · 42 (3)
DOI: 10.1002/btpr.88506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, online erschienen am 05.04.2026. Verfasst von Alexandra Umprecht und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences, R&D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Spectrum Analysis, Raman, Cell Culture Techniques, High-Throughput Screening Assays. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Monoclonal antibody (mAb) titer monitoring is a key capability during process development and optimization, enabling timely decision making and increasing the speed of development. Raman spectroscopy is a prominent process analytical technology (PAT), but resource‐efficient calibration strategies for the development of transferable models are limited. This work demonstrates the development and successful transfer of a calibration model for monoclonal antibody concentration between two different cell lines with varied metabolic profiles expressing different antibodies. The root mean square error of prediction (RMSEP) for titer in the source cell line (0.266 g L −1 ) was comparable to that of the target cell line (0.325 g L −1 ). The transferable model was achieved by conducting a spiking study in a high‐throughput parallel bioreactor system. Different experimental approaches with models trained on spiked versus native samples were compared. This analysis revealed that model transferability was influenced by the degree of correlation of lactate with antibody titer in the source process, emphasizing the importance of process knowledge in the development of Raman calibration models. Overall, the study presents evidence of the feasibility of transferable titer models, marking a significant advancement in process monitoring capabilities for high‐throughput cell culture as well as introducing a generic methodology for calibration of transferable models in the context of upstream bioprocessing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences, R&D, Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria.
- Institute of Chemical, Environmental and Bioscience Engineering, TU Wien, Vienna, Austria.
- Pharmaceutical Sciences, R&D, Takeda Pharmaceutical Company Limited, Lexington, Massachusetts, USA.
- Chemical Engineering, University of Massachusetts Lowell, Lowell, Massachusetts, USA.
ORCID-Profile: Alexandra Umprecht
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Umprecht, A., Uth, N., Kim, H., Spadiut, O., & Yang, Y. (2026). Rapid development of a transferable R aman model using high‐throughput cell culture for monitoring monoclonal antibody titer. Biotechnology Progress, 42(3). https://doi.org/10.1002/btpr.88506
Vancouver
Umprecht A, Uth N, Kim H, Spadiut O, Yang Y. Rapid development of a transferable R aman model using high‐throughput cell culture for monitoring monoclonal antibody titer. Biotechnology Progress. 2026;42(3). doi:10.1002/btpr.88506
BibTeX
@article{Umprecht2026,
author = {Umprecht, Alexandra and Uth, Nicholas and Kim, Haenah and Spadiut, Oliver and Yang, Yang},
title = {Rapid development of a transferable R aman model using high‐throughput cell culture for monitoring monoclonal antibody titer},
journal = {Biotechnology Progress},
year = {2026},
volume = {42},
number = {3},
doi = {10.1002/btpr.88506}
}
EUVIMED